ADVA
1.9.2020 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Colocation Australia (ColoAU), a subsidiary of 5G Networks Limited (ASX: 5GN), has deployed its FSP 3000 OpenFabric™ to give customers flexible and low-cost connectivity with complete freedom to adjust capacity as required. The company’s new national wavelength product uses bandwidth sourced from a range of providers to offer cost-effective long-distance transport. By using ADVA’s open OTN cross-connect technology, ColoAU is now able to optimize links between Australia’s mainland state capital cities and Singapore to offer the lower-speed services that businesses need. Customers can select data rates ranging from 1.25Gbit/s to 50Gbit/s over OTN, Ethernet, SDH/SONET and Fibre Channel interfaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005020/en/
“We’re using ADVA’s technology to solve one of the key problems that small and medium-sized companies face. They no longer need to waste valuable resources in overprovisioning links that end up redundant or obsolete and are able to support growing bandwidth requirements driven by demand. By utilizing the ADVA FSP 3000 OpenFabric™, we’re able to provide elastic bandwidth offerings that can instantly be turned up or down,” said Nic Tippelt, wholesale manager, ColoAU. “Our new national wavelength product lets customers take control. It empowers them to choose high-quality, secure, point-to-point connectivity that supports ever-changing capacity needs.”
The ADVA FSP 3000 OpenFabric™ gives ColoAU and 5GN Wholesale a truly scalable end-to-end architecture and the ability to support a wide range of client interfaces for metro, inter-capital or international connectivity. It enables the company to leverage other service provider and utility networks as its own and offer a unique combination of high capacity and flexibility. The ADVA FSP 3000 OpenFabric™ features open OTN switching technology , which extends the delivery of bandwidth services throughout the network and eliminates the boundaries of legacy OTN solutions. With the new service, ColoAU has become the first company to use the openness, flexibility and scalability of ADVA’s solution in this way.
“Our FSP 3000 OpenFabric™ creates an architecture that’s open, disaggregated and completely future-proof. It gives ColoAU’s customers the freedom to efficiently transport any mix of optical services, and scale as and when needed. By utilizing other networks to flexibly offer a wide range of wavelengths, the company is empowering enterprises across Australia to harness the ideal connectivity for their business needs,” commented Erik Lindberg, VP, sales, APAC, ADVA. “ColoAU’s new national wavelength product provides businesses across Australia and Singapore with an entirely new way to access the capacity they require. It enables them to seize new opportunities without major risk and eliminates wasted capacity and unnecessary cost.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About 5G Networks and Colocation Australia
Colocation Australia is a subsidiary company of 5G Networks. 5G Networks (ASX: 5GN) is a licenced telecommunications carrier operating across Australia. Our mission is to be Australia’s partner of choice for unifying a seamless digital experience for our customers across data connectivity, cloud and data centre services, underpinned by expert managed services in the business and wholesale markets. 5G Networks currently owns and operates its own nationwide highspeed data network with points of presence in all major Australian capital cities. www.5gnetworks.com.au .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005020/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom